$40,000 of CLOVER HEALTH lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Medicare Advantage Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
CLOV Insider Trading Activity
CLOV insiders have traded $CLOV stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 7 sales selling 65,437 shares for an estimated $203,718.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CLOV Hedge Fund Activity
We have seen 86 institutional investors add shares of CLOV stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 3,879,613 shares (-96.7%) from their portfolio in Q3 2025, for an estimated $11,871,615
- MARSHALL WACE, LLP removed 3,523,047 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,780,523
- RENAISSANCE TECHNOLOGIES LLC removed 3,221,559 shares (-41.8%) from their portfolio in Q4 2025, for an estimated $7,570,663
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 2,768,088 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,470,349
- CITADEL ADVISORS LLC removed 2,042,721 shares (-57.9%) from their portfolio in Q3 2025, for an estimated $6,250,726
- BLACKROCK, INC. added 1,885,917 shares (+6.2%) to their portfolio in Q4 2025, for an estimated $4,431,904
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,878,719 shares (-70.7%) from their portfolio in Q4 2025, for an estimated $4,414,989
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CLOV Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for CLOV, check out Quiver Quantitative's $CLOV forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
